Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ERN1 | O75460 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17397884 | 0.88 | GSK3B (0.36) | ERN1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL20861758 | 0.83 | ERN1 (0.35) | ERN1MAPK1 | |
| SCHEMBL15077376 | 0.77 | MEN1 (0.39) | ERN1ALDH1A1 | |
| SCHEMBL17397897 | 0.77 | KDM4E (0.33) | KDM4EALDH1A1HPGDHTTHSD17B10 | |
| SCHEMBL17397866 | 0.73 | LMNA (0.37) | KDM4EERN1ALDH1A1HPGDHSD17B10 | |
| SCHEMBL12665647 | 0.72 | ALDH1A1 (0.46) | ERN1ALDH1A1 | |
| SCHEMBL29458861 | 0.72 | ALDH1A1 (0.46) | ERN1ALDH1A1 | |
| SCHEMBL29398633 | 0.71 | TDP1 (0.37) | ERN1ALDH1A1 | |
| SCHEMBL13073970 | 0.71 | ERN1 (0.46) | ERN1ALDH1A1 | |
| SCHEMBL12468157 | 0.71 | ERN1 (0.43) | ERN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3164404-B1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO CO LTD (JP) | 2019-04-03 | — | — | EP | disclosed |
| EP-3164404-B1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO CO LTD (JP) | 2019-04-03 | — | — | EP | disclosed |
| US-9944660-B2 | Tricyclic benzoxaboroles as antibacterial agents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-9944660-B2 | Tricyclic benzoxaboroles as antibacterial agents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-9944660-B2 | Tricyclic benzoxaboroles as antibacterial agents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-04-17 | — | — | US | disclosed |
| US-20170174709-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| US-20170174709-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| US-20170174709-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| EP-3164404-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016001834-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016001834-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174709-A1 | TRICYCLIC BENZOXABOROLES AS ANTIBACTERIAL AGENTS | REN, ALPI, IKBKE | KDM4E 3131/4885ERN1 907/4885ALDH1A1 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.